Genetically Engineered Bacterial Protein Nanoparticles for Targeted Cancer Therapy
Received 19 November 2020
Accepted for publication 23 December 2020
Published 8 January 2021 Volume 2021:16 Pages 105—117
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Israel (Rudi) Rubinstein
Haiyan Yang,1 Fujie Jiang,1 Xiaojuan Ji,2 Lu Wang,1 Yaotai Wang,1 Liang Zhang,3 Yu Tang,1 Disen Wang,1 Yong Luo,1 Ningshan Li,1 Qi Wang,1 Jianzhong Zou1
1State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, China; Chongqing Key Laboratory of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, People’s Republic of China; 2Department of Ultrasound, Children’s Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders; National Clinical and Research Center of Child Health and Disorders; China International Science and Technology Cooperation Base of Child Development and Critical Disorders; Chongqing Engineering Research Center of Stem Cell Therapy, Chongqing 400016, People’s Republic of China; 3Institute of Ultrasound Imaging, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, People’s Republic of China
Correspondence: Jianzhong Zou
State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing, Yuzhong District 400016, People’s Republic of China
Email [email protected]
Purpose: Cancer treatment still faces big challenges in the clinic, which is raising concerns over the world. In this study, we report the novel strategy of combing bacteriotherapy with high-intensity focused ultrasound (HIFU) therapy for more efficient breast cancer treatment.
Methods: The acoustic reporter gene (ARG) was genetically engineered to be expressed successfully in Escherichia coli (E. coli) to produce the protein nanoparticles-gas vesicles (GVs). Ultrasound was utilized to visualize the GVs in E. coli. In addition, it was injected intravenously for targeted breast cancer therapy by combing the bacteriotherapy with HIFU therapy.
Results: ARG expressed in E. coli can be visualized in vitro and in vivo by ultrasound. After intravenous injection, E. coli containing GVs could specifically target the tumor site, colonize consecutively in the tumor microenvironment, and it could obviously inhibit tumor growth. Meanwhile, E. coli which contained GVs could synergize HIFU therapy efficiently both in vitro and in vivo as the cavitation nuclei. Furthermore, the tumor inhibition rate in the combination therapy group could be high up to 87% compared with that in the control group.
Conclusion: Our novel strategy of combing bacteriotherapy with HIFU therapy can treat breast cancers more effectively than the monotherapies, so it can be seen as a promising strategy.
Keywords: acoustic reporter gene, gas vesicles, targeted cancer therapy, bacteriotherapy, high-intensity focused ultrasound
Cancer therapeutic remains a big challenge in the clinic. The traditional methods of anticancer therapeutics including surgery, chemotherapy, radiotherapy, immunotherapy, and bacteriotherapy have raised the hope for cancer treatment.1 However, there are inevitable side effects including invasiveness, high toxicity, immune system destruction, drug resistance, high costs, and low treatment efficiency.2–4 In recent decades, high-intensity focused ultrasound (HIFU) has shown great potential in clinical therapy of noninvasive solid tumors.5–7 However, the practical application of HIFU for combating cancers is still limited due to its insufficient therapeutic effect.8
To obtain better cancer therapy efficiency through HIFU ablation, synergistic agents (SAs) have recently attracted tremendous attention. Various SAs (eg, gas-filled nanoparticles, lipiodol, hydroxyapatite, and liquid fluorocarbon nanoparticles) are explored to synergize HIFU ablation for tumors by cavitation effect or changing the acoustic properties of the tumor tissue.9–13 Those traditional SAs have been exploited to improve the efficiency for cancer therapy, but the cancer therapy efficiency needs to improve urgently due to i) lack of satisfying tumor-targeting ability; ii) high toxicity; iii) complex preparation process; iv) big size; v) instability; vi) short halftime in blood circulation, and those limitations have led to the unsatisfied efficiency of cancer therapy.
Live tumor-targeting bacteria vectors as the natural “microrobot” raises the new hope for cancer therapy.14–17 Many kinds of obligate or facultative anaerobic bacteria, such as Bifidobacterium,18,19 Salmonella typhimurium (S. typhimurium),20–22 Escherichia coli (E. coli),23–25 Listeria,26 and Clostridium,27,28 not only possess inherent specifically tumor-targeting activities and anti-tumor efficacy but also can be engineered to target and deliver antitumor agents for cancer therapy via genetic programs or sophisticated bio-syntheses.29
To overcome the drawbacks of adding conventional SAs to synergize HIFU ablation for tumors, our team attempts to explore the biological targeting synergistic agents, which utilize the live tumor-targeting bacteria as the vectors to realize more efficient cancer treatment. Our preliminary experiments found that the anaerobic bacterium Bifidobacterium longum (B. longum) was able to specifically target solid tumors after intravenous (i.v.) injection B. longum which served as a vehicle can conjugate and deliver more SAs to the tumor site, synergizing HIFU efficiently for more effective cancer therapy.30–34But this strategy still has some limitations including i) drawbacks of conventional SAs; ii) just connecting SAs to the bacterial surface of B. longum. How to further improve cancer therapy efficiency is crucial, while there is a big challenge to achieve high-efficiency cancer therapy.
Acoustic reporter gene (ARG) is the genetic constructs firstly reported by Mikhail Shapiro35 and could be expressed in E. coli and S. typhimurium. ARG expressed in bacteria could be visualized in vitro and in vivo by ultrasound for it encodes the production of gas vesicles (GVs).36–39 GVs, a unique class of protein-shelled nanoparticles with gas-filled in the interior, is comprised of a 2-nm-thick protein shell with dynamic sizes of typical widths from 45 to 250 nm and lengths from 100 to 600 nm. The special structure of GVs allows dissolved gases to permeate in and out freely and exclude water.40,41 Especially, GVs is capable of nucleating cavitation both in their purified form and inside genetically engineered bacteria.42 In addition, E. coli, as the anaerobic bacteria, can target and colonize in tumor regions after i.v. injection, and quickly be cleared from normal organs.43 Thus, E. coli shows good biosafety. More importantly, E. coli, as the anticancer agents, can inhibit tumor growth by expressing chemotactic receptors to respond to chemotaxis towards molecular signals in the tumor microenvironment.44,45 Therefore, the strategy of utilizing GVs expression in E. coli as the new SA to synergize HIFU ablation for tumors may be an alternative option for enhancing cancer treatment.
To achieve this goal, we report a new approach to treat cancers with profound therapeutic efficacy by combing bacteriotherapy with HIFU therapy. As shown in Figure 1, we firstly genetically engineered the ARG to express in E. coli BL21(AI) to produce GVs in vitro, and then injected E. coli BL21(AI) which contains GVs (hereby named GVs-E. coli) into the tumor-bearing mice to inhibit the tumor growth; finally, we treated the breast cancer by HIFU therapy, tumor volume measurements and histological analyses were used to evaluate the treatment efficiency of breast cancer.
Figure 1 Schematic illustration of the GVs-E. coli for breast cancer therapy combing HIFU therapy and bacteriotherapy.
Abbreviations: GVs, gas vesicles; GVs-E. coli, E. coli BL21(AI) which contains GVs; HIFU, high-intensity focused ultrasound.
Materials and Methods
E. coli BL21(AI) was purchased from Shanghai Weidi Biotechnology Co., Ltd (China) and stored at −80°C before use, the pET28a_T7-ARG1 was a gift from Mikhail Shapiro (Addgene plasmid # 106473). The pQE3_green fluorescent protein (GFP) was a gift from the key laboratory of molecular biology on infection diseases, Chongqing medical university. Luria-Bertani (LB) was purchased from Hopebiol Co., Ltd (China). All chemicals were analytical grade and used without further purification.
For bacterial culture, E. coli BL21(AI) was cultured in LB liquid medium in a shaking incubator (37°C, 220 rpm). Bacterial concentration was estimated spectrophotometrically by determining absorbance at 600 nm, and cell numbers were verified by plating dilutions of inoculum onto LB agar plate (1 OD ≈ 1.06 ×109 CFU/mL). For expression of ARG and GFP in E. coli BL21(AI), the method was adopted from Mikhail Shapiro35 and previously described respectively,46 and the GVs-E. coli was observed directly by transmission electron microscopy (TEM, Hitachi 7500, Japan) and ultrasound using MyLab 90 (Esaote, Italy). Thereafter, E. coli BL21(AI) with or without plasmid was collected by centrifugation (5000 rpm, −20°C, 10 min) and diluted with sterile PBS for further experiments.
The human breast cancer MDA-MB-231 cells were purchased commercially from the Chinese Academy of Sciences Cell Bank (China). The cells were cultured according to ATCC recommended conditions at 37°C with 5% CO2 in DMEM supplemented with 10% FBS and 1% streptomycin/penicillin.
Animals and Model Establishment
All the animal experiments and procedures were approved by the Institutional Animal Care and Use Committee at Chongqing Medical University and performed under their guidelines. Female BALB/c nude mice (20–25 g) and female BALB/c mice (6 to 8 weeks) were supplied by the Laboratory Animal Center of Chongqing Medical University and were housed to drink and eat freely. To establish the tumor model, 0.1 mL PBS solutions (1×106 cells) were subcutaneously injected into the left flank of nude mice. The volume of the tumor was calculated as [0.5 × length × (width)2]. After the tumor diameter reached ~ 0.5mm, all experimental animals were randomly assigned to six groups in the following experiments. The biosafety of E. coli BL21(AI) was evaluated using BALB/c mice.
Evaluation of Safety in vivo
Six groups (n=5 per group) of healthy BALB/c mice (~20 g, 4–6 weeks) were used to assess the in vivo toxicity. 1× 108 CFU live GVs-E. coli (selected from a series of safety experiments including different doses, data not shown) in a total volume of 100 μL phosphate-buffered saline (PBS) solution was injected into mice intravenously (i.v.) in all experiments. The weight of mice was monitored every 2 days over 14 days. Blood samples were collected before (control group) and after 30 minutes,1, 3, 7 and 14 days feeding post-injection for biochemical examinations of complete blood count (white blood cell, WBC; red blood cell, RBC; platelets, PLT; hemoglobin, HGB; mean corpuscular hemoglobin, MCH; mean corpuscular volume, MCV), liver functional markers (alanine aminotransferase, ALT; aspartate transaminase, AST), myocardial enzymogram (creatine kinase, CK; L-lactate dehydrogenase, LDH-L), and kidney functional marker (blood urea nitrogen, BUN; creatinine, CREA). The major organs (heart, liver, spleen, lung, and kidney) were stained with H&E for histological analysis at the corresponding time point.
Tumor-Targeting Ability of E. coli BL21(AI)
Before and after injecting i.v. GVs-E. coli at the dose of 1× 108 CFU/100 μL at the 1st, 3rd, 7th, and 14th day, the major organs (heart, liver, spleen, lung, kidney, and tumor) of mice were extracted at the desired time points, weighed, and homogenized at 4°C in sterile PBS. Those samples were diluted (10-fold, 100-fold, 1000-fold, etc) and spread on LB plates. After 8–24 hours of incubation, the number of GVs-E. coli colonies were counted. The bacterial titer (CFU per gram of tissue) was calculated with colony counts and tissue weights. Single colony was further picked for gram staining.
For in vitro ultrasound imaging, two groups were divided as follows: E. coli and GVs-E. coli. The ultrasound images under B mode and contrast-enhanced ultrasonography (CEUS) mode were acquired using MyLab 90 (Esaote, Italy). The gray value was measured by DFY software (Chongqing, China).
For tumor ultrasound imaging, MDA-MB-231 tumor-bearing nude mice were intratumorally injected with 100 μL (1× 108 CFU), images of the tumor region were obtained by ultrasound, and the quantitative analysis of gray value was measured.
Synergistic Effect of GVs-E. coli for HIFU Therapy
A Model-JC200 Focused Ultrasound Tumor Therapeutic System (Chongqing Haifu Medical Technology Co., Ltd., Chongqing, China) was used for all HIFU experiments. The focal length, diameter, and operating frequency were 100–250 mm, 100–300 mm, and 0.5–2 MHz, respectively. A high-energy US beam was emitted from the therapeutic transducer, while changes in the targeted tissue were monitored by the diagnostic transducer in real-time.
A passive cavitation detector (PCD) was used to detect the cavitation characteristics under atmospheric pressure to compare cavitation behavior during the process of HIFU exposure. Acoustic signal from ex vivo bovine liver and tumors was recorded by the high-speed data acquisition card. Then the signal was programmed to get the corresponding spectrum 90 with fast Fourier transform on the LabView development platform (step length 15ms). The broadband noise was calculated after the band-pass filter (5 MHz) and a band-stop filter (filter passband harmonic).
We used fresh ex vivo bovine livers to evaluate in vitro HIFU ablation efficiency. In brief, 0.1 mL solutions of 1× 108 CFU/mL (PBS, E. coli, and GVs-E. coli) were injected into the bovine livers respectively. Immediately after that, the injection site was treated with HIFU ablation at different power (120 W, 150 W, and 180 W) for 5 s. The emitted signals were recorded with a PCD at the same time. The gray value and coagulative necrosis volume of the ablation area were quantitatively analyzed.
For in vivo HIFU synergistic therapy evaluation, MDA-MB-231 tumor-bearing nude mice (PBS+HIFU, E. coli + HIFU, GVs-E. coli + HIFU) were treated with 0.1 mL solutions at 1× 108 CFU/mL respectively. 7 days after i.v. injection, the tumor site was ablated by HIFU (150 W, 5 s) and detected the cavitation characteristics by PCD. The 2% 2,3,5-triphenyltetrazolium chloride (TTC) solution was used to stain the tumor tissues after 24 h post-HIFU ablation. Gray-scale of the targeted area was automatically compared by the Gray Val 1.0 software affiliated with the HIFU device, coagulative necrosis volume (V) was calculated according to the formula: V (mm3) = π/6 × length× width× depth, and energy efficiency factor (EEF) was measured according to the formula: EEF (J/mm3) = ηPt/V, where η (set to 0.7) means the focusing coefficient of HIFU transducer, P (W) means the power of HIFU, and t (s) means the ablation time.
Evaluation of Anticancer Efficiency of GVs-E. coli
The antitumor efficiency was observed by measuring the body weight and tumor volume using an electronic caliper every 2 days from day 0 to day 21. Relative tumor volume (RTV) was normalized based on the initial tumor volume before the treatment. The tumor inhibition rate (IRT) was calculated by the formula:
IRT = (RTVcontrol group - RTVexperimental group)/RTVcontrol group ×100%
On the 21st day after injection, in order to observe apoptosis and necrosis, nude mice were euthanized and the tumor tissues were harvested for weighting and staining by H&E, terminal-deoxynucleotidyl transferase-mediated nick end labeling (TUNEL), and proliferating cell nuclear antigen (PCNA).
All statistical analyses were performed using SPSS 21.0 program. Data are presented as mean ± standard deviation (SD). Multi-group comparisons were analyzed using one-way ANOVA followed by LSD test or Dunnett’s T3 test (*p < 0.05, **p < 0.01, ***p < 0.001).
Results and Discussion
Characterization of E. coli BL21(AI)
To observe the basic characteristics of E. coli BL21(AI), the gram stain was performed. As Figure 2A shown, E. coli BL21(AI) shows a pale pink, long, and rod shape which was classified as a member of the gram-negative bacterium. E. coli BL21(AI) could grow rapidly under optimal conditions, and it reached the mid-logarithmic phase in 2–4 hours under the LB liquid medium (dilution ratio: 1:100) in a shaking incubator with 220 rpm at 37°C (Figure 2B). To quantify the E. coli BL21(AI), plate dilution was used to count the colony-forming units (CFU) by measuring absorbance value at 600 nm (optical density, OD600). According to the standard curve we calculated (Figure 2C) that the CFU was 1.06×109 in 1 mL of bacterial solutions when OD600=1 (1OD=1.06 × 109 CFU/mL).
In vivo Biosafety Assay of E. coli BL21(AI)
The biosafety of bacteria is a prerequisite for use in vivo experiments and further clinical translation. As shown in Figure 3A, the bodyweight of mice exhibited a slight decrease 3 days after i.v. injection, but quickly showed an upward trend and the growth curve was consistent with the control group, indicating E. coli BL21(AI) treatment had no obvious effects on the body weight. The blood indexes including complete blood count (WBC, RBC, PLT, HGB, MCH, and MCV), liver functional markers (ALT, AST), myocardial enzymogram (CK, LDH-L), and kidney functional marker (BUN, CREA) showed slight fluctuations on day 1 after i.v. injection. At later time points (on day 3, 7, or 14 days after injection), the blood indexes gradually return to the normal level compared with those in the control group, indicating undetectable toxicity in short and relatively long timeframes (Figure 3B). This result is consistent with the previous studies.47 The reason for the slight fluctuation of body weight and the blood indexes in the early time after i.v. injection might be sensitization of immune system, but this phenomenon can quickly disappear, because the E. coli BL21(AI) was cleared by normal organs.48 H&E staining was further used to test the histocompatibility of E. coli BL21(AI). H&E staining of the major organs (heart, liver, spleen, lung, and kidney) at the corresponding time point after i.v. injection showed no significant acute or chronic physiological toxicity when compared with the control group (Figure 3C), indicating the high histocompatibility of E. coli BL21(AI).
Tumor-Targeting Ability of E. coli BL21(AI)
To elaborate the distribution of E. coli BL21(AI) in vivo after i.v. injection, the mice were executed, and the major organs including heart, liver, spleen, lung, kidney, and tumor tissues of mice were weighed, homogenized, and plated on LB plates. It can be observed that bacteria were gradually eliminated from major organs such as the heart, liver, spleen, kidney, and lung. In marked contrast, bacteria were colonized in tumor tissues (Figure 4A). By counting the CFU in each plate, it was found that the CFU in major organs including heart, liver, spleen, kidney, and lung gradually decreased during the time (1, 3,7,14 days after injection). On the contrary, the CFU in tumor tissues increased exponentially following the time points (Figure 4B). Those results were consistent with the previous studies.49 This phenomenon may be attributed to the selected colonization of anaerobes in the hypoxic, immunosuppressive, and biochemically unique tumor microenvironment.50 The single colony on the plate was picked for gram staining. As shown in Figure 4C, the pale pink, long, and rod-shaped bacteria can be observed, the same with Figure 2A, which indicated the bacteria growth in the plate is E. coli BL21(AI).
To further confirm whether GVs-E. coli could be expressed consistently in the tumor site, a green fluorescent protein (GFP) - bearing plasmid was transformed into E. coli BL21(AI) (GFP-E. coli). As shown in Figure 4D, strong green fluorescence was detected in the LB medium with or without ampicillin (Amp). On the contrary, the fluorescence intensity of GFP cultured in PBS was almost invisible, indicating that the target gene expressed in E. coli BL21(AI) could be expressed consistently in the optimum culture conditions. Moreover, to evaluate the ability of consistent expression of GFP-E. coli in vivo, the GFP-E. coli was injected into the MDA-MB-231 tumor-bearing mice intravenously. As shown in Figure 4E, there was no green fluorescence detected in the control group. In marked contrast, green fluorescence was detected in the tumor tissues from day 1 to day 14 after i.v. injection of GFP-E.coli, demonstrating that not only GFP-E.coli could colonize in tumor tissues but also the plasmid would not vanish for a short time in vivo.51
ARG Expressing in E. coli BL21(AI)
TEM was used to further validate whether the GVs was produced successfully in E. coli BL21(AI). A mass of cylindrical or spindle-shaped protein nanostructures can be directly observed in the E. coli BL21(AI) by TEM (Figure 5A), while none can be found in the control group (Figure 5B).
To evaluate the ultrasound imaging capability of GVs-E. coli, we investigated GVs-E. coli in vitro through a gel phantom (Figure 5C), and the corresponding quantitative analysis of gray value was performed (Figure 5D). Compared with those in the control group, both B-mode and CEUS-mode showed obvious echogenicity in GVs-E. coli (***P<0.001), demonstrating that GVs could be detected in vitro by ultrasound imaging. Next, an in vivo tumor ultrasound imaging experiment was performed to determine whether GVs-E. coli could be detected by ultrasound. We investigated the ultrasound imaging of tumors before and after injecting GVs-E. coli (Figure 5E), and the corresponding quantitative analysis of gray value was performed (Figure 5F). As the Figures are shown in Figure 5E and F, before injection, no echogenicity showed in both mode ultrasound images of tumors, and the gray value of tumor images had no obvious difference. In contrast, the echogenicity in both mode ultrasound was significantly enhanced after injecting GVs-E. coli (***P<0.001). The result of ultrasound imaging is consistent with those of previous studies, which confirmed that the GVs produced in E. coli as a contrast agent could be imaged by ultrasound.52,53
GVs-E. coli as HIFU Synergistic Agent by Inertial Cavitation in vitro
Based on the distinct gas-filled protein nanoparticles property of GVs, their ex vivo synergistic effect on HIFU ablation was systematically investigated by employing fresh degassed bovine liver. As shown in Figure 6A, the HIFU ablation volume in all groups increased as adopted ultrasound power increased (120 W, 150 W, and 180 W). The gray-value from real-time ultrasound imaging of the GVs-E. coli group at three levels of HIFU power was significantly higher than that in the other two groups (Figure 6B, *p < 0.05). Similarly, the specific volume of coagulative necrosis of the GVs-E. coli group was significantly larger than that in the other two groups (Figure 6C, *p < 0.05). At the same time, there were no obvious broadband emissions detected during the ultrasound power (120 W, 150 W, and 180 W) in PBS groups (Figure 6D1, D4, and D7) and E. coli groups (Figure 6D2, D5, and D8). Notably, the broadband emissions of GVs-E. coli group showed a significant increase in detected signal amplitude as the power increased (Figure 6D3, D6, and D9). These results suggest that GVs-E.coli was able to improve HIFU-ablation efficacy by serving as nuclei for inertial cavitation.42
Anticancer Efficiency of GVs-E. coli Induced by Combination Therapy
To further evaluate the anticancer efficiency of GVs-E. coli, the synergistic effect of HIFU ablation and tumor growth inhibition through GVs-E. coli were systematically assessed. Figure 7A shows the protocol of this study, HIFU treatment was conducted on 7 days after i.v. injection of GVs-E. coli. As the results are shown in Figure 7B, after HIFU irradiation, the gray value of the tumor target region in all groups (PBS+HIFU, E. coli +HIFU, and GVs-E. coli +HIFU) showed obvious changes compared with the result before HIFU irradiation. Notably, the gray value changes in the GVs-E. coli group were more significant than those in the other two groups (Figure 7B and C, ***p < 0.001). At the same time, we detected the cavitation effect by PCD. The GVs-E.coli group showed obviously higher broadband emissions than the other two groups (Figure 7D), indicating GVs-E. coli could serve as nuclei for inertial cavitation.42 At 24 h after HIFU irradiation, the tumor tissue was harvested for TTC staining and measuring the ablation volumes. As shown in Figure 7E, the coagulative necrosis volume was gray-white (arrowheads indicate points), and the non-ablated regions were red. The gray-white area in the GVs-E. coli group was larger than the other two groups, and the corresponding quantitative coagulative necrosis volume showed the same results as the result of gray value (Figure 7F, ***p < 0.001). Moreover, the value of EEF in various groups showed an opposite trend compared with coagulative necrosis volume and gray value (Figure 7G, **p < 0.01), which means ultrasonic energy for ablating a unit volume of the tumor is the least when using GVs-E. coli as the SA, indicating that GVs-E. coli could be used as a SA for HIFU therapy, and synergized HIFU ablation mainly owing to the cavitation effect.
To further investigate the combination therapeutic effect on tumors, we monitored body weight and the tumor volume changes every 2 days from day 0 to day 21 after i.v. injection (Figure 8A). The bodyweight of mice in the experimental groups except for the HIFU group exhibited a slight decrease in 3 days after i.v. injection, but quickly showed an upward trend and the growth curve was consistent with the control group (Figure 8B), indicating that the combination therapy had no effects on the body weight. As shown in Figure 8C, a significant difference of tumor growth inhibition in all experimental groups was observed compared with the control group, and GVs-E. coli + HIFU group showed the greatest tumor growth inhibition during the observed time (***p<0.001). Moreover, Figure 8D showed that the tumor inhibition rate (87%) of the GVs-E. coli + HIFU group was much higher than that of the HIFU group (75%), E. coli group (66%), GVs-E. coli group (64%), and E. coli + HIFU (77%) (***p<0.001). Furthermore, tumor weight was consistent with that of the variation of tumor volume (insert: digital photos, Figure 8E) (***p<0.001), wherein the GVs-E. coli + HIFU group acquired the lowest tumor weight. These results confirmed that E. coli possess the ability to inhibit tumor growth and the mechanism behind this result is mainly due to: i) bacterial toxins that directly kill cancer cells; ii) cytokines that stimulate immune cells to kill cancer cells; iii) tumor antigens that sensitize the immune system against cancer cells.43 The primary mechanism of HIFU ablation for tumors is the focusing of the ultrasound beam on a point to generate high energy through the thermal effect, cavitation effect, and mechanical effect, which can stimulate protein denaturation and coagulation necrosis of tumor tissues without affecting surrounding normal tissue, thereby achieving non-invasive cancer treatment.54 GVs-E. coli showed the strongest synergistic effects mainly due to the cavitation effect. In this study, the GVs-E. coli + HIFU group showed more effective cancer treatment because the E. coli could first inhibit the tumor growth and then avoid liquefactive necrosis of the tumor, thus facilitating the HIFU ablation for solid tumor tissues.
In addition, the combination therapy effect was assessed via histological analyses such as hematoxylin and eosin (H&E), PCNA, and TUNEL staining. As shown in Figure 8F, a clear boundary between the ablated area and the non-ablated area was observed, and substantial cellular necrosis was observed in GVs-E. coli + HIFU group. Lower proliferative tumor cells were determined by PCNA assay and extensive apoptotic nuclei were observed using TUNEL assay (Figure 8G), demonstrating that the combination therapy can achieve more effective cancer treatment than that of the monotherapies.
In summary, we have treated breast cancer more efficiently by taking the novel strategy of combing bacteriotherapy with HIFU therapy. Detailly, we successfully expressed ARG in E. coli to produce GVs, which is gas-containing protein nanoparticles and could be imaged by ultrasound in vitro and in vivo. The GVs-E. coli exhibited excellent biosafety at a safe tolerated dose. We demonstrated that GVs-E. coli can specifically target the tumor site and inhibit the tumor growth to avoid liquefactive necrosis of the tumor, which is more conducive to HIFU ablation for solid tumors. Moreover, the genetic reconstitution of bacteria protein nanoparticles (GVs-E. coli) could act as the cavitation nuclei to synergize HIFU therapy efficiently. Therefore, GVs-E. coli could act as a potential biological targeting synergistic agent to synergize HIFU therapy for cancers more efficiently. This novel combination strategy also shows great potential in fighting cancers.
We greatly acknowledge the help and selfless sharing from Dr. Mikhail Shapiro and Dr. Zhiyang Jin.
The authors report no conflicts of interest in this work.
1. Cai Y, Liang P, Tang Q, et al. Diketopyrrolopyrrole-Triphenylamine Organic Nanoparticles as Multifunctional Reagents for Photoacoustic Imaging-Guided Photodynamic/Photothermal Synergistic Tumor Therapy. ACS Nano. 2017;11(1):1054–1063. doi:10.1021/acsnano.6b07927
2. Zhou S, Gravekamp C, Bermudes D, Liu K. Tumour-targeting bacteria engineered to fight cancer. Nat Rev Cancer. 2018;18(12):727–743. doi:10.1038/s41568-018-0070-z
3. Zhang C, Sun W, Wang Y, et al. Gd-/CuS-Loaded Functional Nanogels for MR/PA Imaging-Guided Tumor-Targeted Photothermal Therapy. ACS Appl Mater Interfaces. 2020;12(8):9107–9117. doi:10.1021/acsami.9b23413
4. Zhou Y, Hu Y, Sun W, et al. Polyaniline-loaded γ-polyglutamic acid nanogels as a platform for photoacoustic imaging-guided tumor photothermal therapy. Nanoscale. 2017;9(34):12746–12754. doi:10.1039/c7nr04241h
5. Cheng C, Chen W, Zhang L, Wu H, Zink J, Responsive Mesoporous A. Silica Nanoparticle Platform for Magnetic Resonance Imaging-Guided High-Intensity Focused Ultrasound-Stimulated Cargo Delivery with Controllable Location, Time, and Dose. J Am Chem Soc. 2019;141(44):17670–17684. doi:10.1021/jacs.9b07591
6. Kang Y, Kim J, Park J, et al. Tumor vasodilation by N-Heterocyclic carbene-based nitric oxide delivery triggered by high-intensity focused ultrasound and enhanced drug homing to tumor sites for anti-cancer therapy. Biomaterials. 2019;217:119297. doi:10.1016/j.biomaterials.2019.119297
7. Wang Z, Qiao R, Tang N, et al. Active targeting theranostic iron oxide nanoparticles for MRI and magnetic resonance-guided focused ultrasound ablation of lung cancer. Biomaterials. 2017;127:25–35. doi:10.1016/j.biomaterials.2017.02.037
8. Liang X, Gao J, Jiang L, et al. Nanohybrid liposomal cerasomes with good physiological stability and rapid temperature responsiveness for high intensity focused ultrasound triggered local chemotherapy of cancer. ACS Nano. 2015;9(2):1280–1293. doi:10.1021/nn507482w
9. Yildirim A, Chattaraj R, Blum N, Goldscheitter G, Goodwin A. Stable Encapsulation of Air in Mesoporous Silica Nanoparticles: fluorocarbon-Free Nanoscale Ultrasound Contrast Agents. Adv Healthcare Mater. 2016;5(11):1290–1298. doi:10.1002/adhm.201600030
10. Wang S, Zhao J, Hu F, et al. Phase-changeable and bubble-releasing implants for highly efficient HIFU-responsive tumor surgery and chemotherapy. J Mater Chem B. 2016;4(46):7368–7378. doi:10.1039/c6tb01861k
11. Liu T, Zhang N, Wang Z, et al. Endogenous Catalytic Generation of O Bubbles for In Situ Ultrasound-Guided High Intensity Focused Ultrasound Ablation. ACS Nano. 2017;11(9):9093–9102. doi:10.1021/acsnano.7b03772
12. You Y, Wang Z, Ran H, et al. Nanoparticle-enhanced synergistic HIFU ablation and transarterial chemoembolization for efficient cancer therapy. Nanoscale. 2016;8(7):4324–4339. doi:10.1039/c5nr08292g
13. Moncion A, Harmon J, Li Y, et al. Spatiotemporally-controlled transgene expression in hydroxyapatite-fibrin composite scaffolds using high intensity focused ultrasound. Biomaterials. 2019;194:14–24. doi:10.1016/j.biomaterials.2018.12.011
14. Duong M, Qin Y, You S, Min J. Bacteria-cancer interactions: bacteria-based cancer therapy. Exp Mol Med. 2019;51(12):1–15. doi:10.1038/s12276-019-0297-0
15. Kaimala S, Al-Sbiei A, Cabral-Marques O, Fernandez-Cabezudo M, Attenuated A-RB. Bacteria as Immunotherapeutic Tools for Cancer Treatment. Front Oncol. 2018;8:136. doi:10.3389/fonc.2018.00136
16. Sedighi M, Zahedi Bialvaei A, Hamblin M, et al. Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities. Cancer Med. 2019;8(6):3167–3181. doi:10.1002/cam4.2148
17. Yoo J, Irvine D, Discher D, Mitragotri S. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov. 2011;10(7):521–535. doi:10.1038/nrd3499
18. Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084–1089. doi:10.1126/science.aac4255
19. Yazawa K, Fujimori M, Nakamura T, et al. Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Res Treat. 2001;66(2):165–170. doi:10.1023/a:1010644217648
20. Danino T, Lo J, Prindle A, Hasty J, Bhatia S. In Vivo Gene Expression Dynamics of Tumor-Targeted Bacteria. ACS Synth Biol. 2012;1(10):465–470. doi:10.1021/sb3000639
21. Guo Y, Chen Y, Liu X, Min J, Tan W, Zheng J. Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium. Cancer Lett. 2020;469:102–110. doi:10.1016/j.canlet.2019.10.033
22. Chen W, Wang Y, Qin M, et al. Bacteria-Driven Hypoxia Targeting for Combined Biotherapy and Photothermal Therapy. ACS Nano. 2018;12(6):5995–6005. doi:10.1021/acsnano.8b02235
23. Min J, Kim H, Park J, et al. Noninvasive real-time imaging of tumors and metastases using tumor-targeting light-emitting Escherichia coli. Mol Imaging Biol. 2008;10(1):54–61. doi:10.1007/s11307-007-0120-5
24. Zheng D, Chen Y, Li Z, et al. Optically-controlled bacterial metabolite for cancer therapy. Nat Commun. 2018;9(1):1680. doi:10.1038/s41467-018-03233-9
25. Yu YA, Shabahang S, Timiryasova TM, et al. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol. 2004;22(3):313–320. doi:10.1038/nbt937
26. Kim S, Castro F, Paterson Y, Gravekamp C. High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action. Cancer Res. 2009;69(14):5860–5866. doi:10.1158/0008-5472.can-08-4855
27. Chagnon A, Hudon C, McSween G, Vinet G, Fredette V. Cytotoxicity and reduction of animal cell growth by Clostridium M-55 spores and their extracts. Cancer. 1972;29(2):431–434. doi:10.1002/1097-0142(197202)29:2<431::AID-CNCR2820290226>3.0.CO;2-Z
28. Shinnoh M, Horinaka M, Yasuda T, et al. Clostridium butyricum MIYAIRI 588 shows antitumor effects by enhancing the release of TRAIL from neutrophils through MMP-8. Int J Oncol. 2013;42(3):903–911. doi:10.3892/ijo.2013.1790
29. Yu X, Lin C, Yu J, Qi Q, Wang Q. Bioengineered Escherichia coli Nissle 1917 for tumour-targeting therapy. Microb Biotechnol. 2020;13(3):629–636. doi:10.1111/1751-7915.13523
30. Luo Y, Xu D, Gao X, et al. Nanoparticles conjugated with bacteria targeting tumors for precision imaging and therapy. Biochem Biophys Res Commun. 2019;514(4):1147–1153. doi:10.1016/j.bbrc.2019.05.074
31. Chen C, Wang Y, Tang Y, et al. Bifidobacterium-mediated high-intensity focused ultrasound for solid tumor therapy: comparison of two nanoparticle delivery methods. Int j Hyperther. 2020;37(1):870–878. doi:10.1080/02656736.2020.1791365
32. Xu D, Zou W, Luo Y, et al. Feasibility between Bifidobacteria Targeting and Changes in the Acoustic Environment of tumor Tissue for Synergistic HIFU. Sci Rep. 2020;10(1):7772. doi:10.1038/s41598-020-64661-6
33. Wang Y, Chen C, Luo Y, et al. Experimental Study of Tumor Therapy Mediated by Multimodal Imaging Based on a Biological Targeting Synergistic Agent. Int J Nanomedicine. 2020;15:1871–1888. doi:10.2147/ijn.s238398
34. Gao X, Zou W, Jiang B, et al. Experimental Study of Retention on the Combination of Bifidobacterium with High-Intensity Focused Ultrasound (HIFU) Synergistic Substance in Tumor Tissues. Sci Rep. 2019;9:1.
35. Bourdeau R, Lee-Gosselin A, Lakshmanan A, et al. Acoustic reporter genes for noninvasive imaging of microorganisms in mammalian hosts. Nature. 2018;553(7686):86–90. doi:10.1038/nature25021
36. Shapiro M, Goodwill P, Neogy A, et al. Biogenic gas nanostructures as ultrasonic molecular reporters. Nat Nanotechnol. 2014;9(4):311–316. doi:10.1038/nnano.2014.32
37. Szablowski J, Bar-Zion A, Achieving Spatial SM. Molecular Specificity with Ultrasound-Targeted Biomolecular Nanotherapeutics. Acc Chem Res. 2019;52(9):2427–2434. doi:10.1021/acs.accounts.9b00277
38. Maresca D, Lakshmanan A, Lee-Gosselin A, et al. Nonlinear ultrasound imaging of nanoscale acoustic biomolecules. Appl Phys Lett. 2017;110(7):073704. doi:10.1063/1.4976105
39. Lakshmanan A, Lu G, Farhadi A, et al. Preparation of biogenic gas vesicle nanostructures for use as contrast agents for ultrasound and MRI. Nat Protoc. 2017;12(10):2050–2080. doi:10.1038/nprot.2017.081
40. Lakshmanan A, Jin Z, Nety S, et al. Acoustic biosensors for ultrasound imaging of enzyme activity. Nat Chem Biol. 2020;16(9):988–996. doi:10.1038/s41589-020-0591-0
41. Ling B, Lee J, Maresca D, et al. Biomolecular Ultrasound Imaging of Phagolysosomal Function. ACS Nano. 2020;14(9):12210–12221. doi:10.1021/acsnano.0c05912
42. Bar-Zion A, Nourmahnad A, Mittelstein DR, et al. Acoustically Detonated Biomolecules for Genetically Encodable Inertial Cavitation. bioRxiv. 2019:620567. doi:10.1101/620567.
43. Forbes N. Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer. 2010;10(11):785–794. doi:10.1038/nrc2934
44. Ho C, Tan H, Chua K, et al. Engineered commensal microbes for diet-mediated colorectal-cancer chemoprevention. Nat Biomed Eng. 2018;2(1):27–37. doi:10.1038/s41551-017-0181-y
45. Jiang S, Phan T, Nam T, et al. Inhibition of Tumor Growth and Metastasis by a Combination of Escherichia coli –mediated Cytolytic Therapy and Radiotherapy. Mol Ther. 2010;18(3):635–642. doi:10.1038/mt.2009.295
46. Zhang Y, Zhang Y, Xia L, et al. Escherichia coli Nissle 1917 targets and restrains mouse B16 melanoma and 4T1 breast tumors through expression of azurin protein. Appl Environ Microbiol. 2012;78(21):7603–7610. doi:10.1128/aem.01390-12
47. Zhang H, Man J, Liang B, et al. Tumor-targeted delivery of biologically active TRAIL protein. Cancer Gene Ther. 2010;17(5):334–343. doi:10.1038/cgt.2009.76
48. Sznol M, Lin SL, Bermudes D, Zheng L, King I. Use of preferentially replicating bacteria for the treatment of cancer. J Clin Invest. 2000;105(8):1027–1030.
49. Min J, Nguyen V, Kim H, Hong Y, Choy H. Quantitative bioluminescence imaging of tumor-targeting bacteria in living animals. Nat Protoc. 2008;3(4):629–636. doi:10.1038/nprot.2008.32
50. Kasinskas RW, Forbes NS. Salmonella typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis. Cancer Res. 2007;67(7):3201–3209.
51. Zhang Y, Zhang Y, Xia L, et al. Escherichia coli Nissle 1917 targets and restrains mouse B16 melanoma and 4T1 breast tumors through expression of azurin protein. Appl Environ Microbiol. 2012;78(21):7603.
52. Ling B, Lee J, Maresca D, et al. Biomolecular Ultrasound Imaging of Phagolysosomal Function. ACS Nano. 2020;14(9):12210–12221. doi:10.1021/acsnano.0c05912
53. Lakshmanan A, Jin Z, Nety SP, Sawyer DP, Shapiro MG. Acoustic biosensors for ultrasound imaging of enzyme activity. Nat Chem Biol. 2020;16(9):1–9.
54. Ma X, Yao M, Shi J, et al. High Intensity Focused Ultrasound-Responsive and Ultrastable Cerasomal Perfluorocarbon Nanodroplets for Alleviating Tumor Multidrug Resistance and Epithelial-Mesenchymal Transition. ACS Nano. 2020. doi:10.1021/acsnano.0c07287
© 2021 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.